Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase.
Bone Marrow Transplant
; 42(9): 597-600, 2008 Nov.
Article
en En
| MEDLINE
| ID: mdl-18679373
ABSTRACT
Imatinib mesylate (IM) is now first-line treatment for CML. To study the results of treatment with IM after IFN failure/intolerance versus allogeneic BMT (allo-BMT), we retrospectively analyzed 264 patients treated for CML in first chronic phase in three different institutions. Over a 6-year period (2001-2006), 174 patients received IM after failure of or intolerance to IFN. During the same period of time, 90 patients received an allo-BMT from an HLA-matched sibling (n=83) or an unrelated donor (n=7). The IM group was older (41 versus 33 years, P<0.001). Five-year EFS was 62% among patients receiving IM and 52% among patients undergoing allo-BMT (P=0.0002). OS at 5 years was 93% for IM-treated patients and 59% for patients undergoing allo-BMT (P<0.0001). Allo-BMT cannot be considered as first-line treatment for CML patients in first chronic phase.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mieloide de Fase Crónica
/
Trasplante de Células Madre Hematopoyéticas
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Bone Marrow Transplant
Asunto de la revista:
TRANSPLANTE
Año:
2008
Tipo del documento:
Article
País de afiliación:
Brasil